Диссертация (1174200), страница 51
Текст из файла (страница 51)
– № 11. – P. 682-687.214. Korkmaz A. Long-term outcomes in acute pulmonary thromboembolism: theincidence of chronic thromboembolic pulmonary hypertension and associated riskfactors / A. Korkmaz [et al.] // Clinical and applied thrombosis/hemostasis. – 2012.– Т. 18. – № 3. – P. 281-288.215. Ku G.H. Long lives, short indications / G.H. Ku, H.H. Billett // Thrombosis andhaemostasis. – 2005.
– Т. 93. – № 01. – P. 17-22.216. Labas P. The home treatment of deep vein thrombosis with low molecular weightheparin, forced mobilisation and compression / P. Labas [et al.] // Internationalangiology. – 2000. – Т. 19. – № 4. – P. 303-307.217. LaMori J.C. Inpatient resource use and cost burden of deep vein thrombosis andpulmonary embolism in the United States / J.C.
LaMori [et al.] // Clinicaltherapeutics. – 2015. – Т. 37. – № 1. – P. 62-70.218. Langevelde K. van Finding the origin of pulmonary emboli with a total-bodymagnetic resonance direct thrombus imaging technique / K. van Langevelde [et al.]// Haematologica. – 2013. – Т. 98. – № 2. – P. 309-315.308219. Lapidus L. Home treatment of deep vein thrombosis / L. Lapidus [et al.] //Pathophysiology of haemostasis and thrombosis. – 2002. – Т. 32. – № 2. – P. 5966.220.
Laux V. Direct inhibitors of coagulation proteins–the end of the heparin and lowmolecular-weight heparin era for anticoagulant therapy? / V. Laux [et al.] //Thrombosis and haemostasis. – 2009. – Т. 102. – № 11. – P. 892-899.221. Le Conte P. Efficacy of alteplase thrombolysis for ED treatment of pulmonaryembolism with shock / P. Le Conte [et al.] // The American journal of emergencymedicine.
– 2003. – Т. 21. – № 5. – P. 438-440.222. Lee A.Y. Low-molecular-weight heparin versus a coumarin for the prevention ofrecurrent venous thromboembolism in patients with cancer / A.Y. Lee [et al.] //New England journal of medicine. – 2003. – Т. 349. – № 2. – P. 146-153.223. Lee A.Y.
Tinzaparin vs warfarin for treatment of acute venous thromboembolismin patients with active cancer: a randomized clinical trial / A.Y. Lee [et al.] // Jama.– 2015. – Т. 314. – № 7. – P. 677-686.224. Lensing A.W. Deep-vein thrombosis / A.W. Lensing [et al.] // The Lancet. – 1999.– Т.
353. – № 9151. – P. 479-485.225. Levchak I. Choice of fistulas optimal diameter while performance ofthrombectomy from ileo-femoral venous segment / I. Levchak // Klinichnakhirurhiia. – 2015. – № 1. – P. 38-40.226. Levine M.
A comparison of low-molecular-weight heparin administered primarilyat home with unfractionated heparin administered in the hospital for proximaldeep-vein thrombosis / M. Levine [et al.] // New England Journal of Medicine. –1996. – Т. 334. – № 11. – P. 677-681.227. Linkins L.-A. Clinical impact of bleeding in patients taking oral anticoagulanttherapy for venous thromboembolism / L.-A. Linkins, P.T. Choi, J.D. Douketis //Annals of internal medicine. – 2003. – Т.
139. – № 11. – P. 893.228. Lipe D.N. Rare case of unilateral phlegmasia cerulea dolens with bilateral deepvein thrombosis at a community military hospital emergency department / D.N.Lipe, D. Cuthbert // Military medicine. – 2017.
– Т. 182. – № 5-6. – P. 1823-1825.309229. Liu G. Endovascular management of extensive lower extremity acute deep veinthrombosis with AngioJet rheolytic thrombectomy plus catheter-directedthrombolysis from contralateral femoral access / G. Liu [et al.] // Phlebology. –2019. – Т. 34. – № 4. – P.
257-265.230. Louis S.G. Thromboelastogram-guided enoxaparin dosing does not conferprotection from deep venous thrombosis: a randomized controlled pilot trial / S.G.Louis [et al] // Journal of Trauma and Acute Care Surgery. – 2014. – Т. 76. – № 4.– P. 937-943.231. Lyman G.H. Venous thromboembolism prophylaxis and treatment in patients withcancer: American Society of Clinical Oncology clinical practice guideline update /G.H. Lyman, K. Bohlke, A. Falanga // J Oncol Pract. – 2015. – Т. 11. – № 3.
–P. 442-444.232. Machleder H.I. Effort thrombosis of the axillosubclavian vein: a disabling vasculardisorder. / H.I. Machleder // Comprehensive therapy. – 1991. – Т. 17. – № 5. –P. 18-24.233. Marshall P.S. Diagnosis and management of life-threatening pulmonary embolism/ P.S. Marshall, K.S. Mathews, M.D. Siegel // Journal of intensive care medicine.
–2011. – Т. 26. – № 5. – P. 275-294.234. Martí D. Incidencia de hipertensión pulmonar tromboembólica crónica sintomáticay asintomática / D. Martí [et al.] // Archivos de Bronconeumología. – 2010. –Т. 46. – № 12. – P. 628-633.235. Martin M.J. Vena cava filters: current concepts and controversies for the surgeon /M.J. Martin [et al.] // Current problems in surgery.
– 2010. – Т. 7. – № 47. –P. 524-618.236. Mavor G.E. Deep Vein Thrombosis: The Surgical Aspects of Deep VeinThrombosis. / G.E. Mavor, J.M.D. Galloway, A.M. Karmody //SAGEPublications. – 1970. – Т. 63(2) – P. 126-131.237. McAree B.J. Inferior vena cava thrombosis: a review of current practice / B.J.McAree [et al.] // Vascular Medicine. – 2013. – Т.
18. – № 1. – P. 32-43.310238. McLoney E.D. Complications of Celect, Günther tulip, and Greenfield inferiorvena cava filters on CT follow-up: a single-institution experience / E.D. McLoney[et al.] // Journal of Vascular and Interventional Radiology. – 2013. – Т. 24. –№ 11. – P. 1723-1729.239. Meisner R.J. Review of indications and practices of vena caval filters at a largeuniversity hospital / R.J.
Meisner [et al.] // Vascular and endovascular surgery. –2012. – Т. 46. – № 1. – P. 21-25.240. Mellado M. Vena cava filters in patients presenting with major bleeding duringanticoagulation for venous thromboembolism / M. Mellado [et al.] // Internal andemergency medicine. – 2019. – P. 1-12.241. Meltzer A.J. Clinical, demographic, and medicolegal factors associated withgeographic variation in inferior vena cava filter utilization: an interstate analysis /A.J. Meltzer [et al.] // Surgery.
– 2013. – Т. 153. – № 5. – P. 683-688.242. Members A.F. ESC Guidelines on the diagnosis and management of acutepulmonary embolism: The Task Force for the Diagnosis and Management of AcutePulmonary Embolism of the European Society of Cardiology (ESC) Endorsed bythe European Respiratory Society (ERS) / A.F. Members [et al.] // European heartjournal. – 2014.
– Т. 35. – № 43. – P. 3033-3080.243. Merli G. Subcutaneous enoxaparin once or twice daily compared with intravenousunfractionated heparin for treatment of venous thromboembolic disease / G. Merli[et al.] // Annals of internal medicine. – 2001. – Т. 134. – № 3. – P. 191-202.244. Meyer G. Fibrinolysis for patients with intermediate-risk pulmonary embolism / G.Meyer [et al.] // New England Journal of Medicine.
– 2014. – Т. 370. – № 15. –P. 1402-1411.245. Middeldorp S. Duration of treatment with vitamin K antagonists in symptomaticvenous thromboembolism / S. Middeldorp, M.H. Prins, B.A. Hutten // CochraneDatabase of Systematic Reviews. – 2014. – № 8. – P. 1-52.246. Millward S.F. Günther Tulip retrievable vena cava filter: results from the Registryof the Canadian Interventional Radiology Association / S.F. Millward [et al.] //311Journal of Vascular and Interventional Radiology. – 2001.
– Т. 12. – № 9. –P. 1053-1058.247. Ming Z. Risk factors for thrombosis associated with retrievable inferior vena cavafilter placement / Z. Ming [et al.] // Int J Clin Exp Med. – 2016. – Т. 9. – № 7. –P. 12818-12824.248. Mismetti P. Meta‐analysis of low molecular weight heparin in the prevention ofvenous thromboembolism in general surgery / P. Mismetti [et al.] // British Journalof Surgery. – 2001. – Т.
88. – № 7. – P. 913-930.249. Mismetti P. Effect of a retrievable inferior vena cava filter plus anticoagulation vsanticoagulation alone on risk of recurrent pulmonary embolism: a randomizedclinical trial / P. Mismetti [et al.] // Jama. – 2015. – Т. 313. – № 16. – P. 16271635.250. Monreal M. Recurrent pulmonary embolism: a prospective study / M.
Monreal [etal.] // Chest. – 1989. – Т. 95. – № 5. – P. 976-979.251. MoodleyO.Shouldlifelonganticoagulationforunprovokedvenousthromboembolism be revisited? / O. Moodley, H. Goubran // Thrombosis journal.– 2015. – Т. 13. – № 1. – P. 1-9.252. Moore P.S. Trends in vena caval interruption / P.S. Moore [et al.] // Journal ofvascular surgery. – 2010. – Т. 52.
– № 1. – P. 118-125.253. Morales J.P. Decision analysis of retrievable inferior vena cava filters in patientswithout pulmonary embolism / J.P. Morales [et al.] // Journal of Vascular Surgery:Venous and Lymphatic Disorders. – 2013. – Т. 1. – № 4. – P. 376-384.254. Moretz W.H. Experimental studies on temporary occlusion of the inferior venacava / W.H. Moretz, P.F. Naisbitt, G.P. Stevenson // Surgery. – 1954. – Т. 36. –№ 3.
– P. 384-398.255. Moriarty J.M. Inferior vena cava filters: when to place and when to remove / J.M.Moriarty, J.D. Steinberger, A.K. Bansal // Seminars in respiratory and critical caremedicine. – Thieme Medical Publishers, 2017. – Т. 38. – P. 84-93.312256. Moser K.M. Frequent asymptomatic pulmonary embolism in patients with deepvenous thrombosis / K.M. Moser [et al.] // Jama.
– 1994. – Т. 271. – № 3. – P. 223225.257. Moustafa F. Management and outcome of major bleeding in patients receivingvitamin K antagonists for venous thromboembolism / F. Moustafa [et al.] //Thrombosis research. – 2018. – Т. 171. – P. 74-80.258. Muriel A. Survival effects of inferior vena cava filter in patients with acutesymptomatic venous thromboembolism and a significant bleeding risk / A. Muriel[et al.] // Journal of the American College of Cardiology. – 2014. – Т.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
